Rheumatoid Arthritis
Conditions
Interventions
Mox group:grain-sized moxibustion plus methotrexatem
met group:methotrexatem
Sponsors
Chengdu University of TCM
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) diagnosed with RA (accroding to the ACR/EULAR 2010 criteria); (2) between 18 to 65-year-old, DAS28 >3.2; (3) clear consciousness and be able to cooperate with this trail; (4) no other antirheumatic drugs were received within 24 weeks; (5) sign informed consent for clinical study.
Exclusion criteria
Exclusion criteria: (1) unconscious and be unable to complete the study; (2) advanced patients, severe deformity of joint, and the function is in stage IV; (3) with other autoimmune diseases, such as systemic lupus erythematosus, Sjogren's syndrome, and mixed connective tissue disease; (4) with some severe diseases of the heart, brain, lung,liver, kidney, or hematopoietic system; (5) with malignant tumor; (6) women in pregnancy or nursing, (7) diagnosed with a psychiatric disorder; (8) allergic to a variety of drugs; (9) be afraid of the Moxibustion treatment;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| American College of Rheumatology 20 (ACR 20); | — |
Secondary
| Measure | Time frame |
|---|---|
| American College of Rheumatology 50/70 (ACR 50/70);the pain visual analogue scale (VAS);DAS28 score;Health Assessment Questionnaire;Rate of erythrocyte sedimentation;C-reactive protein;Rheumatoid factor; | — |
Countries
China
Contacts
Public ContactWu Ping
Chengdu University of TCM
Outcome results
None listed